Everest Medicines Ltd. has in-licensed a Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of renal diseases from Suzhou Sinovent Pharmaceuticals Co. Ltd. and Sinomab Bioscience Ltd. in a deal worth up to $561 million. Everest gained global rights to develop, produce and commercialize the candidate, XNW-1011.

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: AB Science, Abcellera, Advita Life Science, Aptorum, Beigene, Biontech, Cstone, Golden, Harbour Biomed, Henlius, Hummingbird, Hutchmed, Innocare, Keymed, Moderna, Pfizer, Pharmamar, Redhill, Relief, Sciclone, Scynexis, Takeda, Telix, Tonix, Y-Mabs, Zai Lab.

Data to be presented at ESMO Congress 2021, including: Acepodia, Bridge, Coherus, Cstone, Daiichi Sankyo, Eqrx, Junshi, Laekna Therapeutics Shanghai, Sarah Cannon Research Institute.

Biopharmas in Asia-Pacific raising money in public or private financings: Alebund, Etana, Iaso, Innovent.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Aicuris Anti-Infective Cures, Aivita Biomedical, Appili, Arca, Astellas, Astrazeneca, Atyr, Biontech, Biophytis, Calcimedica, Coherus, Cstone, Daiichi Sankyo, Edesa, Eiger, Eqrx, Gritstone, Hutchmed, Jemincare, Junshi, Pangu, Pfizer, Pharming, Providence, Redhill, Rottapharm, Sumitomo Dainippon, Takis, Urovant Sciences, Valneva, Vicore.

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: 180 Life Sciences, Appili, Arctic Vision, Astrazeneca, Biosplice, Celltrion Healthcare, Celonic, Celsion, Cresset Discovery Services, Curevac, Defence, Elicio, Emergent Biosolutions, Enterome, Everest Medicines, Eyenovia, Fujifilm Toyama Chemical, Gilead Sciences, Glenmark, Hainan Poly, Haisco, Luye, Nanoviricides, Novartis, Novavax, Oragenics, Providence, Rapid Dose, RDIF, Rentschler, Sciclone, Sinomab, Spectrumx, Supertrans Medical, Suzhou Sinovent, Takeda, Tarveda, Theracour, Travere, Vifor, Wacker Chemie.

New hires and promotions in the biopharma industry in Asia-Pacific, including: Aslan, Genequantum Healthcare.

South Korea’s Ministry of Health and Welfare (MHW) is currently discussing the implementation of a preferential drug pricing system and plans to initiate an expert survey in 2022. The preferential drug pricing system is part of a three-prong strategy that South Korea plans to adopt to promote the growth of eight leading companies in the pharmaceutical, medical device and cosmetic industries by 2030.